在阿尔茨海默氏症发病期间,前额皮层脂质变化
Marta Moreno-Rodriguez1, Sylvia E Perez1, Jonatan Martinez-Gardeazabal2
1Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA.
Journal of Alzheimer's disease : JAD
|April 5, 2024
概括
这就是阿尔茨海默病的原因.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默氏病 (AD) 涉及神经退行,具有零星和家族形式.
- 这两种形式的阿尔茨海默病都有共同的病原性事件,包括胆固醇系统和脂质新陈代谢的破坏.
研究的目的:
- 为了识别前额叶皮层中的关键脂质和受体活性.
- 为了将这些发现与阿尔茨海默病进展期间的认知状态相关联.
主要方法:
- 使用MALDI质谱成像 (MSI) 和功能性自发射线.
- 评估了前额叶皮质 (FC) 中的脂/脂和受体活性 (CB1,S1P1,M2/M4).
- 研究了尸检确认的阿尔茨海默病 (AD),轻度认知障碍 (MCI) 和没有认知障碍 (NCI) 的个体.
主要成果:
- 在MCI中,与髓相关的脂质 (DG,PA) 在白质 (WM) 中增加;在AD WM中,PI水平下降.
- 在FC层中发现了离散的脂质积累 (PC,斯芬戈米林).
- 在AD中观察到M2/M4受体活性降低和CB1/S1P1活性改变.
结论:
- 额叶皮层白质脂质变化与AD早期的骨髓质异常稳定有关.
- 保持白质脂质可能为痴呆症提供治疗策略.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.马尔迪-MSI是什么意思自动辐射图像 (Autoradiography) 是一种自动辐射图像.这是一种胆固醇性胆固醇.脂质微小的 脂肪微小的轻度的认知障碍 轻度的认知障碍肌肉性受体的受体是什么更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
832
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
